You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 18, 2024

~ Buy the INREBIC (fedratinib hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR INREBIC

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for INREBIC

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04955938 ↗	A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms	Not yet recruiting	University of Chicago	Phase 1	2021-10-01	The purpose of this research is to gather information on the safety and effectiveness of fedratinib (a drug called a "jak inhibitor" ) in combination with ivosidenib or enasidenib (two anti-cancer drugs). While all three drugs are FDA-approved for various conditions, the US Food and Drug Administration (FDA) has not approved the combination of these drugs for the treatment of rare blood cancers that present Isocitrate dehydrogenase (IDH) mutations, and therefore these drugs can only be given in a research study.
NCT05127174 ↗	Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms	Recruiting	Bristol-Myers Squibb	Phase 1/Phase 2	2021-11-09	The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
NCT05127174 ↗	Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms	Recruiting	H. Lee Moffitt Cancer Center and Research Institute	Phase 1/Phase 2	2021-11-09	The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
NCT05177211 ↗	Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)	Recruiting	Bristol-Myers Squibb	Phase 2	2021-12-15	The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
NCT05177211 ↗	Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)	Recruiting	H. Lee Moffitt Cancer Center and Research Institute	Phase 2	2021-12-15	The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for INREBIC

Condition Name

Chart
Table

Condition Name for INREBIC
Intervention	Trials
Myeloproliferative Neoplasm	4
MDS	1
Blood Cancer	1
Chronic Neutrophilic Leukemia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for INREBIC
Intervention	Trials
Neoplasms	4
Myeloproliferative Disorders	4
Hematologic Neoplasms	1
Blast Crisis	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for INREBIC

Trials by Country

Map
Table

Trials by Country for INREBIC
Location	Trials
United States	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for INREBIC
Location	Trials
Florida	2
New York	1
Illinois	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for INREBIC

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for INREBIC
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	1
Phase 1	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for INREBIC
Clinical Trial Phase	Trials
Recruiting	3
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for INREBIC

Sponsor Name

Chart
Table

Sponsor Name for INREBIC
Sponsor	Trials
Bristol-Myers Squibb	3
H. Lee Moffitt Cancer Center and Research Institute	2
University of Chicago	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for INREBIC
Sponsor	Trials
Other	4
Industry	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.